ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2279

Sociodemographic Features, Health-Related Quality of Life (HRQoL), Previous General Self-Efficacy and Corticosteroids (CS) Are Associated with General Self-Efficacy in Systemic Lupus Erythematosus (SLE) Patients. Data from a Prevalent Latin American Lupus Cohort

Manuel Ugarte-Gil1, Rocío Gamboa-Cárdenas2, Cristina Reategui-Sokolova3, Victor Pimentel-Quiroz2, Claudia Elera-Fitzcarrald4, Jorge M. Cucho-Venegas5, Cesar Pastor-Asurza6, Zoila Rodriguez-Bellido6, Risto Perich-Campos6 and Graciela S Alarcón7, 1Universidad Cientifica del Sur, Lima, Peru, 2Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, 3Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad San Ignacio de Loyola, Lima, Peru, 4Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Privada San Juan Bautista, Lima, Peru, 5Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, 6Hospital Guillermo Almenara Irigoyen, EsSalud/Universidad Nacional Mayor de San Marcos, Lima, Peru, 7Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL

Meeting: ACR Convergence 2023

Keywords: Patient reported outcomes, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Self-efficacy is the belief that one can carry out a behavior necessary to reach a desired goal. A better self-efficacy has been reported as a predictor of better clinical outcomes in SLE patients such as a better HRQoL. However, predictors of a better self-efficacy in SLE patients remain to be identified. The aim of this study is to determine the predictors of a better general self-efficacy in SLE patients.

Methods: Patients from a single-center Peruvian lupus cohort were included. General self-efficacy was measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) general self-efficacy instrument. For this instrument, a score of 50 is the average for a clinical population, a higher score indicates a greater self-efficacy. Potential predictors examined were gender, age at diagnosis, ethnicity, socioeconomic status, educational level, disease duration, disease activity (ascertained with the SLEDAI-2K), damage (ascertained with the SLICC/ACR damage index, SDI), Charlson comorbidity index, CS as prednisone daily dose, antimalarials and immunosuppressive drugs use, HRQoL (assessed with the LupusQoL), fatigue (ascertained with the FACIT-F) and previous general self-efficacy. Univariable and multivariable generalized estimating equations (GEEs) were performed using general self-efficacy in the subsequent visit, and the potential predictive factors in the previous visit. A multivariable model was done using a backward selection procedure with an alpha to stay in the model of 0.05.

Results: 820 visits from 274 patients were included; 256 (93.4%) were women with a mean age at diagnosis of 35.5 (13.3) years. General self-efficacy at baseline was 47.0 (10.0) and during the follow-up it was 46.6 (10.1). In the multivariable model, age at diagnosis, non-White ethnicity, lower socioeconomic status and the daily prednisone dose were negatively associated with general self-efficacy; better physical health and previous general self-efficacy were positively associated with general self-efficacy (table 1)

Conclusion: Age at diagnosis, lower socioeconomic status, non-White ethnicity and the daily prednisone dose predicted a worse self-efficacy; a better physical health and previous general self-efficacy predicted a better general self-efficacy. Further studies are needed to define the best strategies to improve general self´-efficacy in SLE patients.

Supporting image 1


Disclosures: M. Ugarte-Gil: AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Janssen, 5, Pfizer, 5; R. Gamboa-Cárdenas: None; C. Reategui-Sokolova: None; V. Pimentel-Quiroz: None; C. Elera-Fitzcarrald: None; J. Cucho-Venegas: None; C. Pastor-Asurza: None; Z. Rodriguez-Bellido: None; R. Perich-Campos: None; G. Alarcón: None.

To cite this abstract in AMA style:

Ugarte-Gil M, Gamboa-Cárdenas R, Reategui-Sokolova C, Pimentel-Quiroz V, Elera-Fitzcarrald C, Cucho-Venegas J, Pastor-Asurza C, Rodriguez-Bellido Z, Perich-Campos R, Alarcón G. Sociodemographic Features, Health-Related Quality of Life (HRQoL), Previous General Self-Efficacy and Corticosteroids (CS) Are Associated with General Self-Efficacy in Systemic Lupus Erythematosus (SLE) Patients. Data from a Prevalent Latin American Lupus Cohort [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/sociodemographic-features-health-related-quality-of-life-hrqol-previous-general-self-efficacy-and-corticosteroids-cs-are-associated-with-general-self-efficacy-in-systemic-lupus-erythematosus-sl/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sociodemographic-features-health-related-quality-of-life-hrqol-previous-general-self-efficacy-and-corticosteroids-cs-are-associated-with-general-self-efficacy-in-systemic-lupus-erythematosus-sl/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology